The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite-stable metastatic colorectal cancer (AGICC-ALX148 21CRC01).
 
Robert William Lentz
No Relationships to Disclose
 
Junxiao Hu
No Relationships to Disclose
 
Patrick Jud Blatchford
Employment - BioMimetix; Clovis Oncology; Criterium
Consulting or Advisory Role - BioMimetix; Clovis Oncology; Criterium
 
Todd Pitts
Research Funding - ALX Oncology; AstraZeneca; Exelixis; Takeda
 
Alexis Diane Leal
Employment - Elsevier
Leadership - Elsevier
Research Funding - Abbvie (Inst); Arrys Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conjupro Biotherapeutics (Inst); Corcept Therapeutics (Inst); Exelixis (Inst); Hutchison MediPharma (Inst); Takeda (Inst)
 
Sunnie S. Kim
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo/Lilly
Research Funding - Merck
 
S. Lindsey Davis
Consulting or Advisory Role - Genentech
Speakers' Bureau - Allergan (I)
Research Funding - AstraZeneca (Inst); Boston Scientific (I); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Halozyme (Inst); I-Mab (Inst); Incyte (Inst); Merck (Inst); OncoMed (Inst); ORIC Pharmaceuticals (Inst); Roche (Inst); Senhwa Biosciences (Inst); Symphogen (Inst)
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Pfizer (Inst)
Research Funding - Merck (Inst)
 
Aaron James Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
 
Patrick M Boland
Consulting or Advisory Role - Bayer; Guardant Health; Merck; Pfizer
Research Funding - Amgen (Inst); Macrogenics (Inst); Merck (Inst); Processa Pharmaceuticals (Inst)
 
Howard S. Hochster
Stock and Other Ownership Interests - Compass Therapeutics; Processa Pharmaceuticals
Consulting or Advisory Role - Bayer; Genentech; Merck
Speakers' Bureau - Natera
 
Wells A. Messersmith
Honoraria - Research to Practice (Inst)
Consulting or Advisory Role - Criterium (Inst); Five Prime Therapeutics (Inst); Istari Oncology; QED Therapeutics; Zymeworks
Research Funding - ALX Oncology (Inst); Beigene (Inst); CanBas (Inst); D3 (Inst); Exelixis (Inst); FATE Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); RasCal (Inst)